2.72
+0.07(+2.64%)
Currency In USD
| Previous Close | 2.65 |
| Open | 2.66 |
| Day High | 2.78 |
| Day Low | 2.62 |
| 52-Week High | 13.13 |
| 52-Week Low | 2.4 |
| Volume | 91,053 |
| Average Volume | 118,656 |
| Market Cap | 13.4M |
| PE | -0.28 |
| EPS | -9.73 |
| Moving Average 50 Days | 4.48 |
| Moving Average 200 Days | 7.39 |
| Change | 0.07 |
If you invested $1000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, it would be worth $1.82 as of January 16, 2026 at a share price of $2.72. Whereas If you bought $1000 worth of Tempest Therapeutics, Inc. (TPST) shares 5 years ago, it would be worth $99.09 as of January 16, 2026 at a share price of $2.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: T
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: T
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
GlobeNewswire Inc.
Nov 19, 2025 2:00 PM GMT
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected ne